Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David S. Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
24
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Q32 Bio Inc. market cap is $260.64M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Q32 Bio Inc. 52 week high is $23.57 as of November 17, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Q32 Bio Inc. 52 week low is $1.91 as of November 17, 2026.
Q32 Bio Inc. stock price today is $8.29.
Q32 Bio Inc. stock price yesterday was $8.71.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Q32 Bio Inc.'s P/E ratio is 2.48.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Q32 Bio Inc. P/B ratio is 0.8614.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Q32 Bio Inc. 50-day moving average is $9.14.